Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a top stock with high upside potential. Guggenheim gave it a “Buy” rating and a $8.00 price target, expecting a 146.5% surge. Analysts are optimistic about the company’s silevertinib Phase 2 data in the second half of 2025.

Silevertinib’s preclinical profile positions Black Diamond Therapeutics well to meet response rate and progression-free survival metrics. The company’s year-to-date return has outperformed the market by nearly 40%, making now a good time to consider investing in the stock.

Black Diamond Therapeutics is a clinical-stage oncology company based in Cambridge, Massachusetts. While it shows investment potential, other AI stocks may offer greater upside and lower risk. Explore undervalued AI stock options in the free report provided.

For more insights on stock trends, check out “The Best and Worst Dow Stocks for the Next 12 Months” and “10 Unstoppable Stocks That Could Double Your Money.” No disclosures were made.

Read more at Yahoo Finance: Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results